Sugi Predict

Sugi Predict / Compounds / SCHEMBL2489604

SCHEMBL2489604

SCHEMBL2489604

CC(C)(C)OC(=O)N1C[C@H](F)C[C@@H]1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.42
▸ NR1H2 P55055 1/20 0.39
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ HTRA1 Q92743 1/20 0.36
▸ BTK Q06187 1/20 0.35
▸ DPP4 P27487 2/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ PEPD P12955 1/20 0.33
▸ XPNPEP1 Q9NQW7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20811620 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL38017 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL17760125 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192501 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192921 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL1853822 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL641763 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL29038999 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL1334717 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL15116701 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695236-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2026-02-18 — — EP disclosed
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF 1200 PHARMA LLC (US) 2025-05-01 — — US disclosed
US-20250049780-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2025-02-13 — — US disclosed
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-4486444-A1 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS F. Hoffmann-La Roche AG (CH) 2025-01-08 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
WO-2024216094-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. (US) 2024-10-17 — — WO disclosed
US-12070455-B2 Thienopyrrole compounds GILEAD SCIENCES, INC. (US) 2024-08-27 — — US disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 — — WO disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20190030020-A1 Allosteric Modulators of the Mu Opioid Receptor Chiromics, LLC (US) 2019-01-31 — — US disclosed
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 — — EP disclosed
EP-3055302-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS F. Hoffmann-La Roche AG (CH) 2016-08-17 — — EP disclosed
US-20160152621-A1 ARYL LACTAM KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-06-02 — — US disclosed
WO-2015052264-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2015-04-16 — — WO disclosed
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-08-07 — — US disclosed
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-08-07 — — US disclosed
EP-2380892-A1 IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE Daiichi Sankyo Company, Limited (JP) 2011-10-26 — — EP disclosed
WO-2004032834-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2004-04-22 — — WO disclosed
WO-2004022540-A2 PYRIDAZINONE AND PYRIDONE DERIVATIVES AS ADENOSINE ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136582-A1 SELECT KRAS G12C INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS HSD17B10 3478/4885NR1H2 1568/4885CHRM2 4881/4885
US-20160152621-A1 ARYL LACTAM KINASE INHIBITORS AAK1, ADCK1, ANKK1 HSD17B10 1631/4885NR1H2 4064/4885CHRM2 4870/4885
US-20250049780-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 HSD17B10 3762/4885NR1H2 1364/4885CHRM2 3105/4885
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF GRM5, GRIK5, GRM2 HSD17B10 1045/4885NR1H2 371/4885CHRM2 591/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS HSD17B10 3889/4885NR1H2 1539/4885CHRM2 4880/4885
US-12070455-B2 Thienopyrrole compounds SSB, TPMT, LCP2 HSD17B10 3762/4885NR1H2 1364/4885CHRM2 3105/4885
US-20190030020-A1 Allosteric Modulators of the Mu Opioid Receptor OPRM1, OPRK1, OPRD1 HSD17B10 3576/4885NR1H2 218/4885CHRM2 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.